Corrigendum to 'Efficacy and safety of paclitaxel liposome versus paclitaxel in combination with carboplatin in the first-line chemotherapy for ovarian cancer: a multicenter, open-label, non-inferiority, randomized controlled trial' [Journal of the National Cancer Center 4 (2024) 135-141].